Market Insight - Stem cells: the unsteady rise of the East?
This article was originally published in Scrip
South Korea has had an unsteady early relationship with stem cell research and the country has yet to recover fully from the high-profile Hwang Woo-Suk cloning scandal of 2006. This South Korean scientist famously and fraudulently reported to have succeeded in creating human embryonic stem (hES) cells by nuclear transfer. The scandal received widespread coverage in the media and dealt a terrible blow to the country on the embryonic stem cell research stage. Yet, the hero status bestowed on Dr Hwang before his downfall indicated that Asian governments supported, and that their communities were ready for, stem cell therapies.
You may also be interested in...
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.